Optimizing the Management of Endocrine-Resistant HR-Positive Metastatic Breast Cancer
Management of HR-Positive/HER2-Negative Early Breast Cancer: Taking Direction From the Updated Gu...
Understanding the Concerns and Challenges of Patients With HR-Positive/HER2-Negative EBC: Expert ...
Recent Updates in HR-Positive/HER2-Negative Early Breast Cancer: A Deep Dive Into Understanding t...
Evolving Perspectives on HR-Positive Metastatic Breast Cancer: Current Understanding and New Insi...
European Society for Medical Oncology (ESMO)
ASCO 2023 Expert Report in HR positive, HER2 negative breast cancer by Catherine Harper-Wynne
HR-Positive Breast Cancer — An Interview with Dr Sara A Hurvitz on the Role of Endocrine-Based Th...
Optimizing the Management of Endocrine-Resistant HR-Positive Metastatic Breast Cancer: Video Lecture
HR-Positive Breast Cancer — Fourth Annual National General Medical Oncology Summit
Multidisciplinary Team Best Practices to Improve Adherence for High-Risk, HR-Positive/HER2-Negati...
Conceptualizing Guidelines to Manage Patients with HR–Positive, HER2-Negative Early Breast Cancer
HR-Positive Breast Cancer — An Interview with Dr Sara A Hurvitz on the Role of Endocrine-Based Th...
Inside the Issue: Integrating Antibody-Drug Conjugates into the Management of HR-Positive and Tri...
The Role of Biomarkers in HR-Positive/HER2-Negative Early Breast Cancer: From Clinical Analysis t...
Why Do I Need Adjuvant Therapy? Communicating the Risks for HR-Positive, HER2-Negative EBC at Hig...
Potential Role of PROTAC ER Degraders in Therapy for HR-Positive Metastatic Breast Cancer
Inside the Issue: Integrating Antibody-Drug Conjugates into the Management of HR-Positive and Tri...
Global Healthcare Activities Academy
Recent Advances in the Treatment of HR Positive, HER2 Negative Metastatic Breast Cancer
CDK4/6 inhibitor abemaciclib plus fulvestrant improves overall survival in HR-positive/HER2-nega...
HR-Positive Breast Cancer — Fourth Annual National General Medical Oncology Summit
Adjuvant ET +/- 1 year of everolimus in patients with high-risk HR-positive, HER2-negative BC
Clinical Cases in HR-Positive, HER2-Negative Early Breast Cancer: Applying the Latest Evidence
HR–positive advanced breast cancer: Ribociclib improved PFS for pre and perimenopausal women
![Effect of pregnancy on prognosis in YBC patients with HR positive - Video abstract [ID 290566]](/vi/kCw9Nj8-FTA/mqdefault.jpg)
Effect of pregnancy on prognosis in YBC patients with HR positive - Video abstract [ID 290566]
Individualizing the Selection of First-Line Therapy for Patients with HR-Positive Metastatic BC
Integrating Antibody-Drug Conjugates into the Management of HR-Positive and Triple-Negative Metas...
Survival analysis of of CDK4/6 inhibitors andendocrine therapy in HR positive,her2 negative Day1
Canadian Breast Cancer Network
Questions & Experts: A Medical Oncologist Answers your Questions about HR-Positive Breast Cancer